Javascript must be enabled to continue!
Method Development, Validation and Degradation Studies of Imatinib Mesylate by UPLC
View through CrossRef
Background: A simple, reliable and economical method was used for the study of imatinib mesylate. The optimized chromatographic conditions were determined by using a C18 intersil ODS (250 X 4.6 mm X 5µm) and a mobile phase containing phosphate buffer (pH 3.0): Acetonitrile: Methanol (40:30:30) v/v was pumped at 1 ml/min flow rate. The injected sample volume is 20 μL and the analytes were eluted at 254 nm.
Results: The Retention time of imatinib mesylate was 3.503 minutes. The system suitability percentage RSD of imatinib mesylate is 0.27. The Assay of imatinib mesylate was found to be 99.37%.The imatinib mesylate LOD, LOQ values of were found to be 0.901 and 2.73μg/ml. Regression equation was found to be y= 96.59x + 10.76 form linearity calibration graph. Imatinib mesylate was degraded in acid and peroxide stress conditions, and no degradation was obtained in base, photolytic and thermal conditions.
Conclusion: The reliable UPLC method validation data observed that which can be used for analyzing routine quality control. The method is economical due to the run time is reduced, which can be used in regular quality control tests in the industry.
Sciencedomain International
Title: Method Development, Validation and Degradation Studies of Imatinib Mesylate by UPLC
Description:
Background: A simple, reliable and economical method was used for the study of imatinib mesylate.
The optimized chromatographic conditions were determined by using a C18 intersil ODS (250 X 4.
6 mm X 5µm) and a mobile phase containing phosphate buffer (pH 3.
0): Acetonitrile: Methanol (40:30:30) v/v was pumped at 1 ml/min flow rate.
The injected sample volume is 20 μL and the analytes were eluted at 254 nm.
Results: The Retention time of imatinib mesylate was 3.
503 minutes.
The system suitability percentage RSD of imatinib mesylate is 0.
27.
The Assay of imatinib mesylate was found to be 99.
37%.
The imatinib mesylate LOD, LOQ values of were found to be 0.
901 and 2.
73μg/ml.
Regression equation was found to be y= 96.
59x + 10.
76 form linearity calibration graph.
Imatinib mesylate was degraded in acid and peroxide stress conditions, and no degradation was obtained in base, photolytic and thermal conditions.
Conclusion: The reliable UPLC method validation data observed that which can be used for analyzing routine quality control.
The method is economical due to the run time is reduced, which can be used in regular quality control tests in the industry.
Related Results
Abstract 795: Dovitinib exerts potent antitumor effects in gastrointestinal stromal tumors
Abstract 795: Dovitinib exerts potent antitumor effects in gastrointestinal stromal tumors
Abstract
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumours of the gastrointestinal (GI) tract. Although Imatinib is the current first-l...
PB1950 GENERIC IMATINIB FOR THE TREATMENT OF CHRONIC MYELOID LEUKAEMIA‐ CLINICAL EXPERIENCE OVER A SIX YEAR PERIOD
PB1950 GENERIC IMATINIB FOR THE TREATMENT OF CHRONIC MYELOID LEUKAEMIA‐ CLINICAL EXPERIENCE OVER A SIX YEAR PERIOD
Background:Upon the introduction of the first tyrosine kinase inhibitor (TKI), imatinib, the treatment of chronic myeloid leukaemia has radically changed. The very high treatment c...
The Kinase Inhibitor Imatinib Mesylate Potently Inhibits TNF-α Production by Myeloid Cells and Prevents T-Cell-Mediated Hepatic Injury in Mice.
The Kinase Inhibitor Imatinib Mesylate Potently Inhibits TNF-α Production by Myeloid Cells and Prevents T-Cell-Mediated Hepatic Injury in Mice.
Abstract
Imanitib mesylate (Gleevec®) exhibits potent anti-leukemic effects in vitro and in vivo. Despite of it`s well known anti-leukemic effects, the potential of ...
High Rate of BCR-ABL Transcript Undetectability Achieved by Treating with Imatinib Mesylate Very Late CML Patients in Stable CCR after IFN.
High Rate of BCR-ABL Transcript Undetectability Achieved by Treating with Imatinib Mesylate Very Late CML Patients in Stable CCR after IFN.
Abstract
Background. Interferon alfa (IFN a) induces complete cytogenetic response (CCR) in small proportion of CML patients, with almost all of these patients still...
THU295 The Role Of Imatinib In Pediatric Diabetes
THU295 The Role Of Imatinib In Pediatric Diabetes
Abstract
Disclosure: K. Lavelle: None. C. Chamberlain: None. M.S. Anderson: None. M.S. German: None. A. Nip: None. S.E. Gitelman: None.
Background: A ...
Nilotinib as the First Line Therapy in Managing Chronic Myelogenous Leukemia
Nilotinib as the First Line Therapy in Managing Chronic Myelogenous Leukemia
Abstrak: Leukemia mieloid kronis (chronic myeloid leukemia/CML) adalah penyakit klonal dari sel induk hematopoietik, secara sitogenetik ditandai dengan adanya kromosom Philadelphia...
Abstract A4: Withaferin A induces apoptosis in imatinib-resistant CML cells by repressing the Akt signaling pathway
Abstract A4: Withaferin A induces apoptosis in imatinib-resistant CML cells by repressing the Akt signaling pathway
Abstract
Although imatinib therapy of chronic myelogenous leukemia is effective, the resistance to imatinib challenges the treatment of this disease. Therefore, sear...
Successful Peripheral Blood Stem Cell (PBSC) Mobilisation with G-CSF in Patients with Chronic Myeloid Leukaemia Achieving Complete Cytogenetic Remission with Imatinib.
Successful Peripheral Blood Stem Cell (PBSC) Mobilisation with G-CSF in Patients with Chronic Myeloid Leukaemia Achieving Complete Cytogenetic Remission with Imatinib.
Abstract
The clinical studies have demonstrated the efficacy of Imatinib in the induction of hematological remission, cytogenetic remission (CCR) and molecular reduc...

